Human Genome Sciences Submits Biologics License Application To FDA For ZALBIN™

Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.

Go to Source

People who read this also read

• Of Pfizer, a New Treatment for a Rare Disease and Carrot Cells
  Pfizer’s deal today with Israeli biotech Protalix BioTherapeutics to license most of the rights for a promising therapy for a rare disease caught our eye for a number of reasons: The deal gives Pfizer rights to sell a treatment for Gaucher’s disease that will soon go for FDA approval. Pf...
• Progression of Liver Disease
  There are many different types of liver disease. But no matter what type you have, the damage to your liver is likely to progress in a similar way. Whether your liver is infected with a virus, injured by chemicals, or under attack from your own immune system, the basic danger is the same – that you...
• Human Genome Sciences Announces Results Of Randomized Phase 2 Trial Of Mapatumumab In Non-Small Cell Lung Cancer
  Human Genome Sciences, Inc. (Nasdaq: HGSI) announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). The results showed no difference in...
• RTI Biologics™ Launches Two Biologic Implants At Orthopaedic Surgeon Annual Meeting
  RTI Biologics Inc. (RTI) (Nasdaq: RTIX), the Florida-based processor of orthopedic, dental, surgical specialties and other biologic implants, is launching two new biologic implants for use in sports medicine surgeries at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting in New Orlea...
• Shire Provides Update On Biologics License Application (BLA) Filing For REPLAGAL(R) (agalsidase Alfa) With The U.S. Food And Drug Administration (FDA)
  Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces it has received Fast Track designation from the FDA for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease. Shire filed a BLA for REPLAGAL in December 2009. The FDA requested a...